Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with Ulcerative Colitis (UC) who were previously randomized and have completed the 8-week treatment in ACT12688 study with an acceptable safety profile. Patients who for administrative reasons could not be enrolled in the LTS12593 study right after completion of the 8-week treatment in the ACT12688 study must be enrolled within 3 months from the end of the ACT12688 study~* Signed written informed consent for Study LTS12593~Exclusion criteria:~* Patient with any adverse event leading to study drug (active or placebo) treatment discontinuation from ACT12688 study.~* Patient with any abnormalities or adverse events that per investigator judgment would adversely affect patient's participation in the long-term extension study.~* Use of any immunosuppressant (if patient is on immunosuppressant he or she must discontinue immunosuppressant before starting the LTS12593).~* If the patient started biological treatment for UC while waiting to be enrolled in the LTS12593, then he or she must stop the biological treatment and must have 8 weeks of wash out period before starting treatment with SAR339658 (only anti-tumor necrosis factors (TNFs) are allowed)~* Patients exposed to an anti-integrin or any investigational drug administered after the end of treatment in ACT12688~* Positive pregnancy test~* Breast feeding woman~* Women of childbearing potential not protected by highly effective contraceptive method of birth control and/or who are unwilling and unable to be tested for pregnancy.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR339658 (Type: EXPERIMENTAL): SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial

Based on this trial design, predict the completion outcome and termination type (if applicable).